Nello Mainolfi - 17 Oct 2022 Form 4 Insider Report for Kymera Therapeutics, Inc. (KYMR)

Role: Chief Executive Officer, Director
Signature: /s/ Bruce N. Jacobs, as Attorney-in-Fact
Issuer symbol: KYMR
Transactions as of: 17 Oct 2022
Net transactions value: +$124,243
Form type: 4
Filing time: 17 Oct 2022, 20:09:26 UTC
Previous filing: 03 May 2022
Next filing: 08 Dec 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	KYMR	Common Stock	Options Exercise	$66,676	+32,056	+6.4%	$2.08^*	534,255	17 Oct 2022	Direct
transaction	KYMR	Common Stock	Options Exercise	$57,566	+27,676	+5.2%	$2.08^*	561,931	17 Oct 2022	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	KYMR	Stock Option (Right to Buy)	Options Exercise	$0	-32,056	-69%	$0.000000	14,368	17 Oct 2022	Common Stock	32,056	$2.08	Direct	F1
transaction	KYMR	Stock Option (Right to Buy)	Options Exercise	$0	-27,676	-4.8%	$0.000000	546,604	17 Oct 2022	Common Stock	27,676	$2.08	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The shares underlying this stock option vest in forty-eight (48) equal monthly installments following the vesting commencement date of February 7, 2019, subject to the reporting person's continued employment through each vesting date.
F2	The shares underlying this stock option vest in forty-eight (48) equal monthly installments following the vesting commencement date of November 14, 2019, subject to the reporting person's continued employment through each vesting date.